| Drug General Information |
| Drug ID |
D0O3EP
|
| Former ID |
DNCL002921
|
| Drug Name |
SRT2379
|
| Indication |
Type 2 diabetes [ICD9: 250; ICD10:E11]
|
Phase 1 |
[1]
|
|---|
| Company |
Sirtris
|
| Target and Pathway |
| Target(s) |
NAD-dependent deacetylase sirtuin-1 |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
FoxO signaling pathway
|
|
AMPK signaling pathway
|
|
Glucagon signaling pathway
|
|
Amphetamine addiction
|
|
MicroRNAs in cancer
|
|
PANTHER Pathway
|
p53 pathway
|
|
Pathway Interaction Database
|
p73 transcription factor network
|
|
Signaling events mediated by HDAC Class III
|
|
E2F transcription factor network
|
|
HIF-2-alpha transcription factor network
|
|
Signaling events mediated by HDAC Class I
|
|
FoxO family signaling
|
|
Regulation of Androgen receptor activity
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
RORA activates gene expression
|
|
Regulation of HSF1-mediated heat shock response
|
|
Circadian Clock
|
|
WikiPathways
|
Integrated Pancreatic Cancer Pathway
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
Integrated Breast Cancer Pathway
|
|
SREBP signalling
|
|
Androgen receptor signaling pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01018628) A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers. U.S. National Institutes of Health. |
|---|
| REF 2 | SRT2379, a small-molecule SIRT1 activator, fails to reduce cytokine release in a human endotoxemia model. Critical Care 2013, 17(Suppl 4):P8. |
|---|
